Canbridge Pharmaceuticals (HKSE:01228) EBIT per Share : HK$-1.02 (TTM As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Canbridge Pharmaceuticals EBIT per Share?

Canbridge Pharmaceuticals's EBIT per Share for the six months ended in Jun. 2024 was HK$-0.62. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-1.02.

During the past 3 years, the average EBIT per Share Growth Rate was -13.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Canbridge Pharmaceuticals's EBIT per Share or its related term are showing as below:

HKSE:01228' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -48.8 Med: -31.1 Max: -13.4
Current: -13.4

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Canbridge Pharmaceuticals was -13.40% per year. The lowest was -48.80% per year. And the median was -31.10% per year.

HKSE:01228's 3-Year EBIT Growth Rate is ranked worse than
69.79% of 1248 companies
in the Biotechnology industry
Industry Median: 2.8 vs HKSE:01228: -13.40

Canbridge Pharmaceuticals's EBIT for the six months ended in Jun. 2024 was HK$-261.3 Mil.

Canbridge Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Canbridge Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Canbridge Pharmaceuticals EBIT per Share Chart

Canbridge Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.57

-2.35

-13.95

-1.26

-0.95

Canbridge Pharmaceuticals Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT per Share	Get a 7-Day Free Trial					-0.68	-0.61	-0.55	-0.40	-0.62

Canbridge Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Canbridge Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-404.577	/	424.379
=	-0.95

Canbridge Pharmaceuticals's EBIT per Share for the quarter that ended in Jun. 2024 is calculated as

	EBIT per Share		(Q: Jun. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-261.277	/	424.824
=	-0.62

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-1.02

Canbridge Pharmaceuticals (HKSE:01228) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Canbridge Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Canbridge Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Canbridge Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Canbridge Pharmaceuticals Inc (HKSE:01228) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

MF1:Germany

Address

Building 21, No. 388 Xinping Street, Unit 18, 6th Floor, Suzhou Industrial Park, Suzhou, CHN

Website

https://www.canbridgepharma.com

Canbridge Pharmaceuticals Inc is a biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.

Executives

Xue James Qun	2101 Beneficial owner
Athos Capital Limited	2102 Investment manager
Moskey Matthew Love	2201 Interest of corporation controlled by you
Schulte-hillen Friedrich Bela	2201 Interest of corporation controlled by you
Athos Asia Event Driven Master Fund	2101 Beneficial owner
Ctx Pharma Holdings Limited	2101 Beneficial owner
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse
Kolchinsky Peter	2305 Beneficiary of a trust
Ra Capital Management, L.p.	2102 Investment manager
Ra Capital Healthcare Fund Gp, Llc	2201 Interest of corporation controlled by you
Ra Capital Healthcare Fund, L.p.	2101 Beneficial owner
Wuxi Apptec Co., Ltd.
Qiming Corporate Gp Iv, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p.	2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p.	2101 Beneficial owner

Canbridge Pharmaceuticals Headlines

No Headlines